Your session is about to expire
← Back to Search
Aticaprant for Depression (VENTURA-2 Trial)
VENTURA-2 Trial Summary
This trial will compare the antidepressant aticaprant with a placebo as treatment for adults with major depressive disorder and moderate to severe anhedonia who haven't responded to SSRI or SNRI therapy.
VENTURA-2 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowExclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:VENTURA-2 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2017 Phase 2 trial • 163 Patients • NCT02218736VENTURA-2 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have a history of major depression and must not demonstrate a clinically significant improvement (that is, an improvement of more than 20 percent [%] on their HDRS-17 total score) between the first and the second independent HDRS-17 assessments.I am currently on an SSRI or SNRI for depression and it's working okay.My current treatment for depression, including ketamine or ECT, hasn't worked.I am currently on an SSRI or SNRI for depression and it's working well.My current depression and its treatment response are verified by an independent assessment.I've tried 5 or more antidepressants without success in my current depressive episode.My current antidepressant is not the first one I've used for my depression.I have been diagnosed with major depression without psychosis, first occurring before I was 55.My health is stable as confirmed by recent medical exams and tests.
- Group 1: Placebo
- Group 2: Aticaprant
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any dangers to taking Aticaprant?
"There is both efficacy and safety data from Phase 3 clinical trials, so our team has rated the safety of aticaprant as a 3."
Is this clinical trial being conducted at many different hospitals in North America?
"This study is currently being conducted at 21 different locations across North America, including Toronto, Colorado Springs, and Kingston. If you are interested in participating, it is recommended that you choose a location that is closest to you to minimize travel."
What are the eligibility requirements for this clinical trial?
"This particular study is testing potential treatments for anhedonia in patients aged 18 to 74. Right now, the team is looking to enroll 830 people."
Are adults of all ages being recruited for this experiment?
"According to the information available, adults aged 18 to 74 years old can enroll in this clinical trial. There are a total of 203 studies relating to people under the age of 18 and 985 for people over the age of 65."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
What state do they live in?
Why did patients apply to this trial?
What questions have other patients asked about this trial?
How responsive is this trial?
Most responsive sites:
- Clarke Institute of Psychiatry: < 24 hours
- California Neuroscience Research: < 48 hours
- Revive Research Institute: < 48 hours
Typically responds via
Average response time
- < 2 Days
Share this study with friends
Copy Link
Messenger